Theratechnologies Inc
TSX:TH

Watchlist Manager
Theratechnologies Inc Logo
Theratechnologies Inc
TSX:TH
Watchlist
Price: 2.6 CAD 0.78% Market Closed
Market Cap: 119.5m CAD
Have any thoughts about
Theratechnologies Inc?
Write Note

Operating Margin
Theratechnologies Inc

10.7%
Current
-29%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
10.7%
=
Operating Profit
9m
/
Revenue
84.3m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
CA
Theratechnologies Inc
TSX:TH
119.5m CAD
11%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
316.5B USD
28%
US
Amgen Inc
NASDAQ:AMGN
141.2B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.3B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
135.7B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.2B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-22%
Country CA
Market Cap 119.5m CAD
Operating Margin
11%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 316.5B USD
Operating Margin
28%
Country US
Market Cap 141.2B USD
Operating Margin
19%
Country US
Market Cap 117.1B USD
Operating Margin
38%
Country US
Market Cap 105.3B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 135.7B AUD
Operating Margin
26%
Country US
Market Cap 78.2B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 36B EUR
Operating Margin
-22%
No Stocks Found

Theratechnologies Inc
Glance View

Market Cap
119.5m CAD
Industry
Biotechnology

Theratechnologies, Inc. is a pharmaceutical company. The company is headquartered in Montreal, Quebec and currently employs 87 full-time employees. The firm has two approved products: EGRIFTA SV in the United States, and Trogarzo in the United States, the European Union and the United Kingdom. EGRIFTA SV (tesamorelin for injection) is developed for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Trogarzo (ibalizumab-uiyk) is developed for HIV treatment. The treatment is infused every two weeks. The company is a new class of antiretrovirals (ARV), and is a long-acting ARV therapy that can lead to an undetectable viral load in combination with other ARVs. The firm markets its prescription products in the United States, Europe and Canada. Its research pipeline is focused on specialized therapies addressing unmet medical needs in HIV, oncology and non-alcoholic steatohepatitis (NASH).

TH Intrinsic Value
6.47 CAD
Undervaluation 60%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
10.7%
=
Operating Profit
9m
/
Revenue
84.3m
What is the Operating Margin of Theratechnologies Inc?

Based on Theratechnologies Inc's most recent financial statements, the company has Operating Margin of 10.7%.